Back to Frontiers

AI for Science

High70%

Scientific discovery, drug design, materials science, and AI-driven research acceleration. Accelerating humanity's understanding of the world.

AlphaFolddrug-discoverymaterialshypothesis-generationproteingenomics
22
Papers
23
Milestones
$0
Funding
1
Benchmarks

Key Benchmarks

AlphaFold Accuracy

Protein structure prediction accuracy (GDT score)

92.4%Human: 95%
Leader: AlphaFold2 (CASP14)high saturation

Recent Papers

Discrete Diffusion Language Models for Interactive Radiology Report Drafting

Max Van Puyvelde, Halil Ibrahim Gulluk, Wim Van Criekinge +1 more

Jul 3, 2026HuggingFacePDF

PairSAE: Mechanistic Interpretability from Pair Representations in Protein Co-Folding

Giosue Migliorini, Aristofanis Rontogiannis, Grigori Guitchounts +3 more

Jun 29, 2026ArXivPDF

Multi-Objective Molecular Generation with Frequency-Controlled Evolutionary Dynamics

Elia Colleoni, Paolo Guida, Didier Barradas-Bautista +1 more

Jun 29, 2026ArXivPDF

A Global Context-Aware Deep Neural Network for Enhanced Brain Tumor Segmentation using Magnetic Resonance Images

Sourjya Mukherjee, Ananya Bhattacharjee, R. Murugan

Jun 1, 2026ArXivPDF

Frontier LLM-based Agents Can Overcome the Ontology Curation Bottleneck for Natural Phenotypes

James P. Balhoff, Hilmar Lapp

May 29, 2026ArXivPDF

VFEAgent: A Multimodal Agent Framework for End-to-End Automated Finite Element Analysis

Jiachen Zhang, Junyi Lao, Chenghao Liu +5 more

May 29, 2026ArXivPDF

Heterogeneous Scientific Foundation Model Collaboration

Zihao Li, Jiaru Zou, Feihao Fang +6 more

May 1, 2026HuggingFacePDF

Intern-Atlas: A Methodological Evolution Graph as Research Infrastructure for AI Scientists

Yujun Wu, Dongxu Zhang, Xinchen Li +10 more

May 1, 2026HuggingFacePDF

PR3DICTR: A modular AI framework for medical 3D image-based detection and outcome prediction

Daniel C. MacRae, Luuk van der Hoek, Robert van der Wal +5 more

Apr 6, 2026ArXivPDF

Neuro-Symbolic Activation Discovery: Transferring Mathematical Structures from Physics to Ecology for Parameter-Efficient Neural Networks

Anas Hajbi

Jan 19, 2026ArXivPDF

Recent Milestones

Claude Science Makes AI a Lab Co‑Researcher

Anthropic has launched Claude Science, an AI workbench that unifies scientific databases, tools and compute into a single environment for researchers. The product, announced June 30 and covered widely on July 1, 2026, runs on existing Claude models such as Opus 4.8 and includes features like multi-agent workflows, citation checking and grants of up to $30,000 for selected projects.([anthropic.com](https://www.anthropic.com/news/claude-science-ai-workbench?id=Claude4&utm_source=openai))

Jul 1, 2026releaseImpact: 80/100

Claude helps prove decade‑old jamming conjecture

On July 1, 2026 Phys.org reported that physicists Giorgio Parisi and Francesco Zamponi used Anthropic’s Claude model as a collaborator to help prove a 10‑year‑old conjecture in jamming theory. Claude reproduced prior numerical work and suggested a key idea that the researchers refined into a full mathematical proof.

Jul 1, 2026breakthroughImpact: 70/100

AutoLabs Agents Drive 5–10x Faster Robot Science

On June 25, 2026, the U.S. Department of Energy’s Pacific Northwest National Laboratory unveiled AutoLabs, an agentic AI system that translates scientists’ experimental goals into detailed instructions for an autonomous lab robot. PNNL says AutoLabs can boost experimental throughput by 5–10x and has been open-sourced alongside a Scientific Reports paper.

Jun 25, 2026paperImpact: 70/100

AI Finds New Antibiotics for Drug‑Resistant Gonorrhoea

On June 18, 2026, Open Access Government reported that researchers at Harvard’s Wyss Institute, MIT and the Broad Institute used a deep learning workflow to screen ~6 million compounds and identify new candidates effective against multidrug‑resistant Neisseria gonorrhoeae. The work, detailed in Science Translational Medicine and a Wyss Institute release from June 17, shows AI‑discovered compounds targeting previously underused bacterial pathways with promising in vitro and in vivo results. ([openaccessgovernment.org](https://www.openaccessgovernment.org/machine-learning-identifies-new-compounds-to-target-antibiotic-resistant-gonorrhoea/210692/))

Jun 18, 2026breakthroughImpact: 70/100

Bezos’ Prometheus: $41B bet on ‘General Engineer’ AI

In a June 11, 2026 Financial Times interview republished by Chile’s Diario Financiero, Jeff Bezos said AI will usher in multiple “golden ages” rather than mass job destruction. He outlined his vision for Prometheus, a new AI lab valued at about $41 billion that aims to apply AI to manufacturing and engineering.([df.cl](https://www.df.cl/internacional/ft/jeff-bezos-asegura-que-la-ia-traera-edades-doradas-y-no-una-destruccion))

Jun 11, 2026fundingImpact: 90/100

AI designs first universal coronavirus vaccine

A Cambridge-led team has completed the first human trial of a ‘universal’ coronavirus vaccine whose key antigen was designed entirely by artificial intelligence, with early results published June 5, 2026. Coverage on June 5–6 reports the DNA vaccine was safe in 39 volunteers and generated modest but promising immune responses against the Sarbeco coronavirus family. ([sciencedaily.com](https://www.sciencedaily.com/releases/2026/06/260605023357.htm?utm_source=openai))

Jun 6, 2026paperImpact: 70/100

OpenAI Launches Rosalind Biodefense With GPT-Rosalind

On May 29, 2026, OpenAI launched the Rosalind Biodefense program to sponsor vetted developers building biodefense and pandemic preparedness tools with its life-sciences model GPT‑Rosalind. The company also began extending trusted access to GPT‑Rosalind for select U.S. government and allied public‑health and biodefense agencies, after briefing the White House and several federal bodies on the effort.([openai.com](https://openai.com/index/strengthening-societal-resilience-with-rosalind-biodefense/))

May 29, 2026releaseImpact: 80/100

AlphaProof Nexus cracks open Erdős problems

Google DeepMind said on May 26, 2026 that its AlphaProof Nexus system has formally solved nine open Erdős problems and 44 OEIS conjectures using Lean-verified proofs. CEO Demis Hassabis stressed the system is “still not AGI” but positions it as a new tool for rigorous mathematical research.

May 26, 2026breakthroughImpact: 90/100

GalaxyVS Screens 100B Molecules in Seconds

Chinese media report that researchers at the National Supercomputing Center in Tianjin and Tsinghua University have deployed "GalaxyVS", an AI-driven virtual screening platform built on the DrugCLIP model. According to MyDrivers, the system can perform sub-second retrieval over a 100‑billion–molecule library by mapping protein pockets and ligands into a shared vector space on Tianhe supercomputers.([toolify.ai](https://www.toolify.ai/daily-ai-news))

May 25, 2026breakthroughImpact: 70/100

Robin AI Scientist Automates Months of Lab Work

Nonprofit FutureHouse has published a Nature paper unveiling "Robin", a multi-agent AI system that autonomously generates hypotheses, designs experiments and analyzes wet-lab data. An AIbase report on May 25, 2026 highlights that Robin completed roughly four months (around 900 hours) of human research work in about two hours and identified a candidate treatment for dry age-related macular degeneration.([toolify.ai](https://www.toolify.ai/daily-ai-news))

May 19, 2026breakthroughImpact: 90/100

Anthropic’s $400M Bet on AI Drug Discovery

Anthropic has acquired stealth AI biotech startup Coefficient Bio in an all‑stock deal worth roughly $400 million, pulling a sub‑10‑person team of ex‑Genentech researchers into its healthcare and life sciences unit in early April 2026. The deal, reported by multiple outlets and confirmed by sources close to Anthropic, aims to apply Claude‑style foundation models to end‑to‑end drug discovery workflows.([winbuzzer.com](https://winbuzzer.com/2026/04/05/anthropic-acquires-coefficient-bio-400m-ai-pharma-startup-xcxwbn/))

Apr 5, 2026fundingImpact: 70/100

Anthropic bets $400M on AI drug discovery

On April 4, 2026, multiple outlets reported that Anthropic has acquired New York–based AI biotech startup Coefficient Bio in an all‑stock deal valued at about $400 million. The roughly nine‑person team will join Anthropic’s life sciences unit to build domain‑specific models for drug discovery and biomedical R&D.

Apr 4, 2026fundingImpact: 70/100

Anthropic Buys Coefficient Bio for $400M

Anthropic has acquired New York–based biotech startup Coefficient Bio in a deal valued at about $400 million, mostly in stock. The move, reported on April 3, 2026, folds Coefficient Bio’s biology-focused AI team into Anthropic’s Health Care Life Sciences group to apply Claude models to drug R&D and clinical strategy.

Apr 3, 2026fundingImpact: 80/100

Insilico Opens ‘Science Gym’ for Frontier LLMs

On January 22, 2026, Insilico Medicine announced a new ‘Science MMAI gym’ service designed to train general‑purpose LLMs such as GPT and Qwen to perform better on biology and chemistry tasks. The Hong Kong‑listed biotech says its pipeline can boost model performance by up to 10x on key scientific benchmarks using domain datasets, reward models and reinforcement learning.

Jan 22, 2026releaseImpact: 70/100

GPT‑5.2 helps solve long‑standing Erdős problem

On January 18, 2026, Eclipse founder Neel Somani said he used OpenAI’s GPT‑5.2 Pro to solve Erdős Problem #281, a number theory problem open since 1980. Fields Medalist Terence Tao and other mathematicians reviewed and accepted the proof, and OpenAI president Greg Brockman highlighted the result as a major milestone for AI-assisted science.

Jan 18, 2026breakthroughImpact: 90/100

Merge Labs raises $250M for brain–AI links

Brain‑computer interface startup Merge Labs emerged from stealth with a reported $252 million seed round, led by OpenAI and other investors. Coverage on January 16 highlights the lab’s plan to build high‑bandwidth, largely noninvasive BCIs that integrate tightly with advanced AI systems.

Jan 16, 2026fundingImpact: 80/100

KAIST AI maps B‑ and T‑cell targets for cancer vaccines

A joint team from KAIST and biotech firm Neogenlogic announced an AI model that predicts which tumor neoantigens will trigger robust B-cell and T-cell responses, enabling personalized cancer vaccine design. The model, validated on large genomic and clinical datasets, is described as the first AI framework to jointly model B-cell immunogenicity and T-cell responses, with clinical trials targeted for 2027.

Jan 2, 2026paperImpact: 80/100

AI Designs Personalized Cancer Vaccines by 2027

On January 2, 2026, a joint team from KAIST and Korean biotech firm Neogenlogic disclosed an AI platform that predicts both B cell and T cell responses to tumor neoantigens to design personalized cancer vaccines. The group says the framework, detailed in a December 3 Science Advances paper, is the first to jointly model B cell immunogenicity for vaccine design and is being readied for an IND filing with the U.S. FDA targeting clinical trials in 2027.

Jan 2, 2026paperImpact: 70/100

Nobel Prize for AlphaFold

Demis Hassabis and John Jumper awarded Nobel Prize in Chemistry for AlphaFold.

Oct 9, 2024breakthroughImpact: 95/100

Nobel Prize for Neural Networks

Geoffrey Hinton and John Hopfield awarded Nobel Prize in Physics for foundational neural network work.

Oct 8, 2024breakthroughImpact: 90/100

Leading Organizations

DeepMind
Isomorphic Labs
Google Research
Meta

ArXiv Categories

cs.AIcs.LGq-biophysicschem-ph

Related Frontiers